image
Healthcare - Medical - Specialties - NASDAQ - US
$ 11.01
-8.25 %
$ 368 M
Market Cap
-11.84
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one DCTH stock under the worst case scenario is HIDDEN Compared to the current market price of 11 USD, Delcath Systems, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one DCTH stock under the base case scenario is HIDDEN Compared to the current market price of 11 USD, Delcath Systems, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one DCTH stock under the best case scenario is HIDDEN Compared to the current market price of 11 USD, Delcath Systems, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DCTH

image
$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
31 M REVENUE
1402.03%
-12.4 M OPERATING INCOME
67.50%
-26.4 M NET INCOME
44.66%
-18.7 M OPERATING CASH FLOW
40.22%
-981 K INVESTING CASH FLOW
95.02%
39.4 M FINANCING CASH FLOW
-23.89%
15.1 M REVENUE
57.95%
3.04 M OPERATING INCOME
341.38%
-3.4 M NET INCOME
-182.30%
-1.01 M OPERATING CASH FLOW
72.36%
-15.2 M INVESTING CASH FLOW
-2084.79%
40.4 M FINANCING CASH FLOW
1985.39%
Balance Sheet Delcath Systems, Inc.
image
Current Assets 73.8 M
Cash & Short-Term Investments 53.2 M
Receivables 10.9 M
Other Current Assets 9.64 M
Non-Current Assets 2.83 M
Long-Term Investments 0
PP&E 2.83 M
Other Non-Current Assets 0
69.50 %14.22 %12.58 %3.69 %Total Assets$76.6m
Current Liabilities 6.14 M
Accounts Payable 961 K
Short-Term Debt 105 K
Other Current Liabilities 5.08 M
Non-Current Liabilities 1.7 M
Long-Term Debt 933 K
Other Non-Current Liabilities 766 K
12.25 %64.75 %11.90 %9.77 %Total Liabilities$7.8m
EFFICIENCY
Earnings Waterfall Delcath Systems, Inc.
image
Revenue 31 M
Cost Of Revenue 0
Gross Profit 31 M
Operating Expenses 43.4 M
Operating Income -12.4 M
Other Expenses 14 M
Net Income -26.4 M
40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)31m031m(43m)(12m)(14m)(26m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-40.01% OPERATING MARGIN
-40.01%
-85.07% NET MARGIN
-85.07%
-38.38% ROE
-38.38%
-34.45% ROA
-34.45%
-17.59% ROIC
-17.59%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Delcath Systems, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -26.4 M
Depreciation & Amortization 229 K
Capital Expenditures -559 K
Stock-Based Compensation 9.77 M
Change in Working Capital 0
Others -2.29 M
Free Cash Flow -19.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Delcath Systems, Inc.
image
Wall Street analysts predict an average 1-year price target for DCTH of $23 , with forecasts ranging from a low of $22 to a high of $24 .
DCTH Lowest Price Target Wall Street Target
22 USD 99.82%
DCTH Average Price Target Wall Street Target
23 USD 108.90%
DCTH Highest Price Target Wall Street Target
24 USD 117.98%
Price
Max Price Target
Min Price Target
Average Price Target
24242222202018181616141412121010886644May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Delcath Systems, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? Here is how Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year. zacks.com - 2 weeks ago
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to six individuals whose employment commenced in January and February of 2025. The grants resulted in the right to purchase 264,000 shares of the Company'. businesswire.com - 3 weeks ago
Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript Delcath Systems, Inc. (NASDAQ:DCTH ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Corp Marie Thibault - BTIG Sudan Loganathan - Stephens Bill Maurer - ClearStreet Yale Jen - Laidlaw & Company Chase Knickerbocker - Craig-Hallum Capital Group Swayampakula Ramakanth - H.C. Wainwright Operator Greetings and welcome to the Delcath Systems' Fourth Quarter 2024 Earnings Conference Call. seekingalpha.com - 1 month ago
Delcath Systems, Inc. (DCTH) Beats Q4 Earnings and Revenue Estimates Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.48 per share a year ago. zacks.com - 1 month ago
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial Results Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively HEPZATO KIT™ fourth quarte. businesswire.com - 1 month ago
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of metastatic uveal melanoma (mUM). Our proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System. businesswire.com - 1 month ago
Are You Looking for a Top Momentum Pick? Why Delcath Systems, Inc. (DCTH) is a Great Choice Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 1 month ago
Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 33.74%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 33.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 1 month ago
Biotech walks a 'tightrope' amid unclear funding, regulations Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street senior equity analyst and director of research, Mara Goldstein, sits down with Julie Hyman and Josh Lipton on Market Domination to discuss how to play the biotech sector as Trump's second term in the White House is underway. youtube.com - 2 months ago
Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. zacks.com - 2 months ago
Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. zacks.com - 2 months ago
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of an individual whose employment commenced on November 4, 2024. The grant totaled the right to purchase 30,000 shares of the Company. businesswire.com - 3 months ago
8. Profile Summary

Delcath Systems, Inc. DCTH

image
COUNTRY US
INDUSTRY Medical - Specialties
MARKET CAP $ 368 M
Dividend Yield 0.00%
Description Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Contact 1633 Broadway, New York, NY, 10019 https://www.delcath.com
IPO Date May 3, 2018
Employees 96
Officers Dr. Michael Brunner M.D. Senior Vice President of Interventional Oncology Ms. Sandra Pennell CPA Chief Financial & Accounting Officer Mr. David Hoffman J.D. General Counsel, Corporate Secretary & Chief Compliance Officer Mr. Gerard J. Michel MBA, MS Chief Executive Officer & Director Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. Chief Medical Officer Dr. Martha S. Rook Ph.D. Chief Operating Officer Dr. Johnny John M.D. Senior Vice President of Clinical Operations & Medical Affairs